You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Recent years have witnessed key developments in the diagnosis and treatment of tuberculosis. Alongside this, and running in direct opposition to this progress, was the COVID-19 pandemic, which had an unprecedented detrimental effect on tuberculosis control and the achievement of targets set by the End TB Strategy. This timely and important Monograph provides a crucial update on recent changes, developments and setbacks in the field, and calls for a re-commitment to the achievement of the End TB Strategy and Sustainable Development Goals. Written by authors from across the world, the Monograph covers: diagnosis; advances in treatment; prevention; and tuberculosis control challenges in different populations and contexts.
The lung forms an integral part of the body's immune system and is subject to a range of diseases which are either autoimmune in nature or have clear-cut immunological abnormalities. "Autoimmune Aspects of Lung Disease" provides a concise review of the lung's role in the immune system and a detailed account of both primary and secondary lung diseases which are characterised by immunological perturbation or frank autoimmunity. The volume presents a detailed, up-to-date account of disorders ranging from infection to neoplasia and is written in both an informative and stimulating style by a prestigious group of authors. The chapters are extensively referenced and provide numerous insights into the aetiopathogenesis and clinical features and treatment of immunologically-linked pulmonary disease. The book is intended as both an overview for physicians and scientists with an established interest in diseases of the lung, immunologists seeking to learn more about relevant disorders in the lung and general physicians, whether specialists or in training, seeking to enrich their knowledge of the links between the pulmonary and immune systems.
Tuberculosis continues to kills more people than any other single infective agent. The resurgence of the disease in many countries has produced a heightened awareness of the threat posed by mycobacterial infections. At the same time, there has been an explosion of knowledge of the fundamental properties of mycobacteria, most notably the determination of the complete genome sequence of Mycobacterium tuberculosis. This book provides an up-to-date account of these developments in the molecular biology and immunology of mycobacteria, coupled with allied advances of a more applied nature, such as the use of molecular techniques for diagnosis and epidemiological investigations. With chapters contr...
Introduces new material that reflects the significant advances and developments in the field of clinical laboratory immunology. • Provides a comprehensive and practical approach to the procedures underlying clinical immunology testing. • Emphasizes molecular techniques used in the field of laboratory immunology. • Updates existing chapters and adds significant new material detailing molecular techniques used in the field. • Presents guidelines for selecting the best procedures for specific situations and discusses alternative procedures. • Covers aspects of immunology related disciplines such as allergy, autoimmune diseases, cancers, and transplantation immunology.
Entirely updated and revised, the 6th edition of Clinical Tuberculosis continues to provide the TB physician with a definitive and erudite account of the latest techniques in diagnosis, treatment and control of TB, including an overview of the latest guidelines from the CDC and WHO. With an increased emphasis on the clinical aspects and treatment, this book will be an invaluable resource to the TB practitioner in public health or clinical practice and an ideal reference to laboratory staff. Key Features Completely updated and reorganized Includes brand new chapters on radiology and an overview of the latest WHO, ATS/CDC/IDSA, ERS, NICE, CTS and IUATLD guidelines Clinically focused to provide up-to-date guidance on diagnosis, treatment and control Edited by three renowned experts in the field of tuberculosis
Dissection of the specificity of host immune responses following infection with Mycobacterium tuberculosis is essential for designing effective vaccination and diagnostic biomarkers as well as for better understanding of immunopathogenesis of active tuberculosis. The articles in this volume of the Topics in Microbial Immunology review the significance of this area of research from both experimental models and clinical surveys. This includes T cell recognition of MHC permissive epitopes, use of algorithms for genome-based prediction of immunodominant epitopes, evaluation of candidate antigens/epitopes and adjuvants for vaccination and immunodiagnosis. Future research strategies indicate the need for better understanding of the relationship between epitope specificity and the phenotype of responding T cells and search for biomarkers with a capacity to discriminate and predict the change from latent infection to active disease. These research avenues have important potentials for improving the prevention and control of tuberculosis.
MIMS' Medical Microbiology and Immunology is loved internationally for its thorough yet easy-to-follow coverage of microbiology, infectious diseases, and immunology as a dynamic interplay between microbes and host. Covering the fundamentals of these closely linked disciplines, MIMS' takes a systems approach to elaborate on epidemiology, clinical presentation, pathogenesis, and diagnostic approaches, as well as treatment and infection control considerations, supplemented by case-based examples. Complex scientific and clinical concepts are explained clearly and simply with the help of illustrations and a range of accompanying online content. Students will come away with a deep understanding of...
BACKGROUND: Latent tuberculosis infection (LTBI), defined as a state of persistent immune response to prior-acquired Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB, affects about one-third of the world's population. Approximately 10% of people with LTBI will develop active TB disease in their lifetime, with the majority developing it within the first five years after initial infection. Currently available treatments have an efficacy ranging from 60% to 90%. Systematic testing and treatment of LTBI in at-risk populations is a critical component of WHO's eight-point framework adapted from the End TB Strategy to target pre-elimination and, ultimately, el...